达芦那韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "达芦那韦" in Chinese language version.

refsWebsite

Global rank Chinese rank

14nih.gov

4^th place

5^th place

13web.archive.org

1^st place

9doi.org

2^nd place

23^rd place

4semanticscholar.org

11^th place

332^nd place

3fda.gov

447^th place

581^st place

2drugs.com

399^th place

208^th place

2hivandhepatitis.com

low place

2archive.org

6^th place

4^th place

1purdue.edu

850^th place

1,160^th place

1handle.net

102^nd place

492^nd place

1prezista.com

low place

1europa.eu

68^th place

209^th place

archive.org

King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
Eron, J. HIV-1 Protease Inhibitors. Clinical Infectious Diseases. 2000, 30: 160–170. PMID 10860901. doi:10.1086/313853 .

doi.org

MacArthur, Rodger. Darunavir: Promising Initial Results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Leonis, G.; Czyznikowska, Z.; et al. Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps. J. Chem. Inf. Model. 2012, 52 (6): 1542–1558. PMID 22587384. doi:10.1021/ci300014z.
King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
Lascar, R. M.; Benn, P. Role of darunavir in the management of HIV infection. HIV/AIDS: Research and Palliative Care. 2009, 1: 31–39. PMC 3218677 . PMID 22096377. doi:10.2147/hiv.s5397.
Li, D.; Zhang, Y.; et al. Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation. J. Molecular Modeling. 2014, 20 (2): 2122. PMID 24526384. S2CID 23262721. doi:10.1007/s00894-014-2122-y.
McKeage, K; Perry, CM; Keam, SJ. Darunavir. Drugs. 2009, 69 (4): 477–503. PMID 19323590. doi:10.2165/00003495-200969040-00007.
MacArthur, Rodger D. Darunavir: promising initial results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Liu, F.; Kovalevsky, A.Y. Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir. J. Mol. Biol. 2008, 381 (1): 102–115. PMC 2754059 . PMID 18597780. doi:10.1016/j.jmb.2008.05.062.
Eron, J. HIV-1 Protease Inhibitors. Clinical Infectious Diseases. 2000, 30: 160–170. PMID 10860901. doi:10.1086/313853 .

drugs.com

Darunavir. The American Society of Health-System Pharmacists. [28 November 2016]. （原始内容存档于10 November 2016）.
Darunavir (Prezista) Use During Pregnancy. Drugs.com. 23 October 2018 [21 April 2020]. （原始内容存档于2016-12-20）.

europa.eu

ema.europa.eu

Prezista EPAR. European Medicines Agency (EMA). [21 April 2020]. （原始内容存档于2019-06-25）. 本文含有此來源中屬於公有领域的内容。

fda.gov

FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs. U.S. Food and Drug Administration (FDA) (新闻稿). [2016-11-10]. （原始内容存档于2016-11-13）.
HIV/AIDS Historical Time Line 2000 - 2010. U.S. Food and Drug Administration. 5 January 2018 [21 April 2020]. （原始内容存档于1 June 2019）.

accessdata.fda.gov

Drug Approval Package: Prezista (Darumavir) NDA #021976. U.S. Food and Drug Administration (FDA). 6 September 2006 [21 April 2020]. （原始内容存档于2016-07-01）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

hivandhepatitis.com

hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Efficacy and Safety of Boosted Darunavir (Prezista) Are Superior to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial, 2008-10-28, URL 互联网档案馆的存檔，存档日期2009-07-19..
hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Darunavir (Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive Patients, Caution Urged for Pregnant Women, 2008-10-24, URL 互联网档案馆的存檔，存档日期2009-05-19..

nih.gov

ncbi.nlm.nih.gov

MacArthur, Rodger. Darunavir: Promising Initial Results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Leonis, G.; Czyznikowska, Z.; et al. Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps. J. Chem. Inf. Model. 2012, 52 (6): 1542–1558. PMID 22587384. doi:10.1021/ci300014z.
King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
Lefebvre, E.; Schiffer, C. A. Resilience to Resistance of HIV-1 Protease Inhibitors: Profile of Darunavir. AIDS Rev. 2008, 10 (3): 131–142. PMC 2699666 . PMID 18820715.
Lascar, R. M.; Benn, P. Role of darunavir in the management of HIV infection. HIV/AIDS: Research and Palliative Care. 2009, 1: 31–39. PMC 3218677 . PMID 22096377. doi:10.2147/hiv.s5397.
Li, D.; Zhang, Y.; et al. Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation. J. Molecular Modeling. 2014, 20 (2): 2122. PMID 24526384. S2CID 23262721. doi:10.1007/s00894-014-2122-y.
McKeage, K; Perry, CM; Keam, SJ. Darunavir. Drugs. 2009, 69 (4): 477–503. PMID 19323590. doi:10.2165/00003495-200969040-00007.
MacArthur, Rodger D. Darunavir: promising initial results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Liu, F.; Kovalevsky, A.Y. Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir. J. Mol. Biol. 2008, 381 (1): 102–115. PMC 2754059 . PMID 18597780. doi:10.1016/j.jmb.2008.05.062.
Eron, J. HIV-1 Protease Inhibitors. Clinical Infectious Diseases. 2000, 30: 160–170. PMID 10860901. doi:10.1086/313853 .

aidsinfo.nih.gov

Darunavir / Cobicistat. AIDSinfo. U.S. Department of Health and Human Services. [29 June 2018]. （原始内容存档于3 March 2020）.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (PDF). Department of Health and Human Services. 18 December 2019 [21 April 2020]. （原始内容 (PDF)存档于13 August 2020）. 简明摘要.

dailymed.nlm.nih.gov

Prezista- darunavir tablet, film coated Prezista- darunavir suspension. DailyMed. 6 June 2019 [21 April 2020]. （原始内容存档于2019-02-06）.

files.aidsinfo.nih.gov

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (PDF). Department of Health and Human Services. 18 December 2019 [21 April 2020]. （原始内容 (PDF)存档于13 August 2020）. 简明摘要.

prezista.com

Drug Monograph, Prezista. （原始内容存档于2016-11-11）.

purdue.edu

chem.purdue.edu

HIV/AIDS Research. Purdue Chemistry: The Ghosh Laboratory. [24 June 2021]. （原始内容存档于2021-06-24）.

semanticscholar.org

api.semanticscholar.org

MacArthur, Rodger. Darunavir: Promising Initial Results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
Li, D.; Zhang, Y.; et al. Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation. J. Molecular Modeling. 2014, 20 (2): 2122. PMID 24526384. S2CID 23262721. doi:10.1007/s00894-014-2122-y.
MacArthur, Rodger D. Darunavir: promising initial results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.

web.archive.org

Darunavir. The American Society of Health-System Pharmacists. [28 November 2016]. （原始内容存档于10 November 2016）.
Darunavir (Prezista) Use During Pregnancy. Drugs.com. 23 October 2018 [21 April 2020]. （原始内容存档于2016-12-20）.
Prezista- darunavir tablet, film coated Prezista- darunavir suspension. DailyMed. 6 June 2019 [21 April 2020]. （原始内容存档于2019-02-06）.
HIV/AIDS Research. Purdue Chemistry: The Ghosh Laboratory. [24 June 2021]. （原始内容存档于2021-06-24）.
Darunavir / Cobicistat. AIDSinfo. U.S. Department of Health and Human Services. [29 June 2018]. （原始内容存档于3 March 2020）.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (PDF). Department of Health and Human Services. 18 December 2019 [21 April 2020]. （原始内容 (PDF)存档于13 August 2020）. 简明摘要.
hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Efficacy and Safety of Boosted Darunavir (Prezista) Are Superior to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial, 2008-10-28, URL 互联网档案馆的存檔，存档日期2009-07-19..
hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Darunavir (Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive Patients, Caution Urged for Pregnant Women, 2008-10-24, URL 互联网档案馆的存檔，存档日期2009-05-19..
Drug Monograph, Prezista. （原始内容存档于2016-11-11）.
Prezista EPAR. European Medicines Agency (EMA). [21 April 2020]. （原始内容存档于2019-06-25）. 本文含有此來源中屬於公有领域的内容。
FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs. U.S. Food and Drug Administration (FDA) (新闻稿). [2016-11-10]. （原始内容存档于2016-11-13）.
HIV/AIDS Historical Time Line 2000 - 2010. U.S. Food and Drug Administration. 5 January 2018 [21 April 2020]. （原始内容存档于1 June 2019）.
Drug Approval Package: Prezista (Darumavir) NDA #021976. U.S. Food and Drug Administration (FDA). 6 September 2006 [21 April 2020]. （原始内容存档于2016-07-01）.